New drug cocktail aims to outsmart untreatable bile duct cancer

NCT ID NCT07691515

Not yet recruiting Disease control Sponsor: Zhejiang Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This clinical trial tests a new approach for people with a type of bile duct cancer that cannot be removed by surgery. It compares a combination of targeted therapy and a procedure that delivers chemotherapy directly to the liver against standard chemotherapy. The goal is to see if the new combination helps people live longer and with a better quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tislelizumab, Lenvatinib, Gemcitabine, Cisplatin
What this could lead to: If successful, this could offer a more effective first-line treatment option for people with unresectable intrahepatic cholangiocarcinoma, potentially improving survival and quality of life.
What could go wrong: This is an early-stage Phase 3 trial with a relatively small number of participants. The combination therapy may cause significant side effects, and it is not yet known if it will be better than the standard chemotherapy regimen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma Cirrhosis, Familial, with Pulmonary Hypertension intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRAHEPATIC CHOLANGIOCARCINOMA (ICC)

Contacts and locations

Locations

Ganzhou Hospital-Nanfang Hospital, Southern Medical University

Ganzhou, Jiangxi, 341000, China
Guangdong Second People's Hospital

Guangzhou, Guangdong, 510317, China
Jiangmen Central Hospital

Jiangmen, Guangdong, 529030, China
Jinhua Municipal Central Hospital

Jinhua, Zhejiang, 321000, China
Jinshazhou Hospital of Guangzhou University of Chinese Medicine

Guangzhou, Guangdong, 510168, China
Lishui Central Hospital

Lishui, Zhejiang, 323020, China
NingBo Medical Center Lihuili Hospital

Ningbo, Zhejiang, 315048, China
NingBo No.2 Hospital

Ningbo, Zhejiang, 315010, China
The Affiliated Hospital of QingDao University

Qingdao, Shandong, 266000, China
The Affiliated Panyu Central Hospital of Guangzhou Medical University

Guangzhou, Guangdong, 511400, China
The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330209, China
The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 510060, China
The Second Affiliated Hospital of Guangdong Medical University

Guangzhou, Guangdong, 524003, China
The Second Xiangya Hospital of Central South University

Changsha, Hunan, 410011, China
The Third Xiangya Hospital of Central South University

Changsha, Hunan, 410013, China
West China School of Medicine/West China Hospital, Sichuan University (WCSM/WCH, SCU)

Chengdu, Sichuan, 610041, China
Wuhan Union Hospital of China

Wuhan, Hubei, 430022, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.